Galapagos to buy UK's Inpharmatica

Dutch biotech Galapagos NV has agreed to buy the UK's Inpharmatica for €12.5 million in shares. Inpharmatica will become part of Galapagos' drug discovery services business, BioFocus DPI. Galapagos was also bullish about the acquisition's impact on its use of predictive modeling to pick drug targets.

- see this press release
- here's the AFX report on the acquisition deal

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.